This site is intended for U.S. health care professionals only.

Coding and reimbursement information

Provide billing and coding information for claim submission

Claim appeals process overviews

  • Provide assistance in understanding denied claims and/or underpaid claims, if any, by informing provider of the appeals processes
  • Provide sample letter of medical necessity for appeal, if applicable
  • Once provider submits appeal, follow up with payer to determine outcome

Alternative funding and other options

  • Refer patients to alternate funding sources, such as nonprofit patient assistance foundations, if eligible

For coding and reimbursement information, please call the ORBACTIV® Support Programs at:

1-844-ORBACTIV (1-844-672-2284) Monday - Friday, 8:00 AM - 8:00 PM ET

To download the Reimbursement Guide and Sample Billing Form, please click the PDF file below

Orbactiv® (oritavancin) for injection reimbursement guide

To download the complete list of ICD 10 codes that can be used with ORBACTIV®, please click the PDF file below

Complete list of ICD 10 codes that can be used with ORBACTIV®,

To download the ORBACTIV® Physician/Patient Assistance Form, please click the PDF file below

Orbactiv® (oritavancin) for injection patient assistance form


Content provided for informational purposes only. This information does not guarantee coverage or payment. Codes, coverage, and payment may vary from setting to setting, and from insurer to insurer. The provider submitting a claim is solely responsible for the accuracy of the codes submitted and for compliance with all coverage and reimbursement policies.

Decisions to prescribe ORBACTIV® are by providers working with their patients. The ORBACTIV® Assistance Program provides information about ORBACTIV® and about assistance that may be available to patients who meet certain criteria, including that they are not insured by a federal health care program. More information is available through the ORBACTIV® Assistance Program.

The Medicines Company does not guarantee, and assumes no responsibility for the quality, availability, or scope of the ORBACTIV® Assistance Program services. The Medicines Company reserves the right to rescind, revoke, or amend this offer at any time without notice. Void where prohibited by law.

Important Safety Information


Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after ORBACTIV® administration because the activated partial thromboplastin time (aPTT) test results are expected to remain falsely elevated for approximately 120 hours (5 days) after ORBACTIV® administration.

ORBACTIV® is contraindicated in patients with known hypersensitivity to ORBACTIV®.

Warnings and Precautions

Coagulation test interference: ORBACTIV® has been shown to artificially prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hours, ACT for up to 24 hours, and D-dimer for up to 72 hours.

Hypersensitivity reactions have been reported with the use of antibacterial agents including ORBACTIV®. Discontinue infusion if signs of acute hypersensitivity occur. Monitor closely patients with known hypersensitivity to glycopeptides.

Infusion-related reactions have been reported. Slow the rate or interrupt infusion if infusion reaction develops.

Clostridium difficile-associated colitis: Evaluate patients if diarrhea occurs.

Concomitant warfarin use: Patients should be monitored for bleeding if concomitantly receiving ORBACTIV® and warfarin.

Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.

Prescribing ORBACTIV® in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions (≥3%) in patients treated with ORBACTIV® were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.

See Full Prescribing Information

This site is intended for U.S. Healthcare Professionals. If you are a U.S. Healthcare Professional, click OK to continue.